

# Embase

全球最权威的生物医学、药理学信息数据库




# Agenda

- Embase 数据库涵盖的内容与特点
- Embase VS Pubmed
- Embase 主题词表和检索方法
- Embase在药物以及疾病检索等方面的应用
  1. 关于某个药物的临床试验(Clinical Trial)文献的查询
  2. 关于拓展某个药物的适应症(indications)的查询
  3. 查询他汀类药物不良反应

# Embase数据库涵盖的 内容与特点



# EMBASE数据库发展历程



- Excerpta Medica Abstract Journals (1947/8)

- EMBASE database online (1974)



- EMBASE integrated with Medline (2003)

- EMBASE becomes Embase (2009)

Embase®

# EMBASE数据库简介

全球最佳的生物医学数据库，涵盖期刊以及学术会议摘要索引

## 内容广泛: 确保您不会错过任何有用信息

帮助您发现其他数据库无法找到的信息

## 深度索引: 确保从大量研究文献中找到相关的实时更新的生物医学信息以及文章

来自所有相关的、最新的生物医学研究文献

## 精准搜寻: 找出最相关的结果

深入准确地关注研究信息，强有力的信息提取工具

- 超过8600种期刊
- 超过2800种期刊在Medline数据库上无法检索到
- 尤其是那些在北美以外国家的期刊
- 每年有来约7000个会议的超过295万条的会议摘要(since 2009)\* 独有的信息资源
- 基于Emtree生命科学同义词汇编词库做深入的药物以及医疗设备信息索引

1. Emtree收录 > 73,000个词汇，约为MeSH的2.5倍
2. 每年更新3次



Embase.com  
~ 3180万篇文献  
8600 种期刊

MEDLINE  
~ 2300万文献  
5600 种期刊

PubMed  
~ 2500万篇文献

# EMBASE收录的文献领域...


## 完全涵盖同行评审的生物医学期刊和会议



**其他学科28%**  
Including public health, basic biomedical MEDLINE 包含公共卫生、基础生物医学以及Medline包含的学科领域

# EMBASE收录的文献地域范围...


8,600 JOURNAL TITLES (JUNE 2015)



\* RoW = Rest of the World (esp. Australia & New Zealand, Africa, South America)

# EMBASE VS. MEDLINE(内容)

Includes all Medline content plus much more



- 超过8600种期刊
- 超过2800种期刊在 **Medline** 数据库上无法检索到
- 尤其是那些在北美以外国家的期刊
- 每年有来约7000个会议的超过295万条的会议摘要 (since 2009)
- 基于Emtree生命科学同义词汇编词库做深入的药物以及医疗设备信息索引
- 所含词汇术语数量是 Pubmed (Medline) 数据库同义词汇编词库MeSH的两倍以上



## Embase vs Medline收录文章语言比较 (过去五年)

Language	Embase (per year) *	MEDLINE (per year) *	Unique in Embase
English **	877,186 (90%)	664,207 (92%)	213,000
Chinese	27,861 (2.9%)	11,523 (2.2%)	16,300
German	17,051 (1.7%)	7,421 (1.0%)	9,600
French	13,491	8,469	5,000
Spanish	12,582	6,839	5,700
Japanese	7,762	5,761	2,000
Russian	6,275	6,094	200
Portuguese	4,918	3,560	1,400
Polish	3,479	1,791	1,700
Turkish	3,264	545	2,700
Italian	2,880	1,522	1,400
Dutch	2,618	899	1,700
Czech	1,557 (0.16%)	585 (0.08%)	1,000

比较分类	Embase (total)	MEDLINE	Embase独家收录
文献总量	3180万	2300万	880万
期刊数量	8600种	5600种	3000种
收录范围	全球超过70个国家	北美	欧洲, 亚洲以及其他新兴国家
会议论文	295万条会议摘要 (since 2009)	0	295万条
索引词汇	(Emtree, 完全包括 MeH 词汇)	MeH	研发/实验室代码, 以及数千个医疗过程相关词汇
索引体系	机器学习+人工效验 深度挖掘全文信息	标题摘要和关键词	全文深度索引
更新速度	每天更新 每日更新超过6000条记录	每天更新 每日更新3000条	每天更新超过3000条文献
检索方式	Search Advance search Drug Disease PICO	Search Advance search	Drug Disease PICO

## Embase收录的亚洲期刊数量一览 (2014)

Country	Embase (total)	MEDLINE	Unique in Embase
India	234	48	186
Japan	221	154	67
China	149	88	61
South Korea	62	21	41
Pakistan	34	5	29
Singapore	30	10	20
Taiwan	18	8	10
Hong Kong	14	3	11
Bangladesh	11	3	8
Malaysia	10	4	6
Nepal	7	5	2
Thailand	6	4	2
Indonesia	2	1	1
Sri Lanka	2	1	1
Philippines	2	1	1

# Embase与常规文章以及一些文摘数据库的区别

- Searches focus on different content

Embase专注于摘要对全文进行索引，通过文本挖掘获取全文中的所有关键信息。

Archives of Biochemistry and Biophysics 431 (2005) 149–176

Contents lists available at ScienceDirect

Archives of Biochemistry and Biophysics

Journal homepage: [www.elsevier.com/locate/ybbiol](http://www.elsevier.com/locate/ybbiol)

### Comparison of NMR structural and dynamics features of the urea and guanidine-denatured states of GED

Jeeender Chugh<sup>1</sup>, Shilpi Sharma<sup>1</sup>, Ramakrishna V. Hosur<sup>1\*</sup>

<sup>1</sup>Department of Chemical Sciences, Indian Institute of Technology Bombay, 1, Scheme Building Road, Mumbai-400075, India

**ARTICLE INFO**

Article history:  
Received 13 September 2004  
Received in revised form 2 November 2004  
Available online 9 November 2004

**Keywords:**  
CEDP effector domain  
NMR  
Resonance assignment  
Self-assembly  
Urea-denatured state

**ABSTRACT**

Denatured states of proteins, the starting point as well as the intermediates of folding in vivo, also impart an role in biological functions. In this context, we compare here urea unfolding and characterization of urea-denatured state of a GFP effector domain by NMR data. These are compared with similar data for guanidine induced denaturation reported earlier. The unfolding characteristics as measured by optical probes, are significantly different, urea unfolding proceeding via an intermediate. The structural and motional characteristics, determined by NMR, of the two denatured states are also strikingly different. The urea-denatured state shows a combination of  $\alpha$ - and  $\beta$ -sheet structures in the protein backbone. The  $\beta$ -sheet structure is predominant in the guanidine denatured state. Higher  $T_2$  relaxation rates suggest higher folding propensities in the urea-denatured state. The implications of these to GFP folding are discussed.

© 2005 Elsevier Inc. All rights reserved.

---

Denatured states of proteins are beginning to be recognized as important entities in the biological world—a denatured state of a protein is defined as the lowest energy ‘non-native’ state under a given set of conditions [1]. Inside a living cell, the environmental conditions like local intracellular concentrations, interaction with various ligands etc. can vary significantly from organelle to organelle [2], and even within the same organelle there can be variations due to signaling processes and interactions with different molecules. All these processes tightly regulate the translational and post-translational processes which decide the fate of a newly synthesized polypeptide chain. Thus a particular protein may see different environments which had different denatured state characterizing the course of its function. Some of the denatured states may lead to stable aggregates, which occasionally lead to diseases [3].

When a polypeptide chain begins to fold starting from a denatured ensemble, each molecule in the ensemble can, in-principle, fold along a different path. In this scenario, the starting state in terms of the conformational preferences across the polypeptide chain will have a significant influence on the path the molecule adopts; different denaturing environments inside a cell can create different initial states for the protein to fold from. If the chain already has some structure, that may form the nucleus for additional structure to build upon, and this will reduce the search options for the subsequent chain in the multi-dimensional conformational well details about the perturbations caused by 97 M urea using NMR and finally compare the urea-mediated unfolding with that using Gdn-HCl. Gdn-HCl is highly charged as compared to urea which is neutral and this is expected to have an influence on the unfolding mediated by the two denaturants; the former may lead to more collapsed state due to electrostatic screening. Our data reveal that the unfolding mechanisms by the two denaturants are indeed different. Whereas Gdn-HCl unfolding is two-state [3], urea-mediated unfolding is more complex and hence the structural and dynamics characteristics of the denatured states created by the two are different. These provide clues about the differences in the potential folding initiation sites for the folding that may follow on dilution of the denaturant. This study will form the basis for a detailed elucidation of the urea dilution driven self-association pathway of the protein, along the same lines as has been recently demonstrated in the case of self-association driven by guanidine dilution [7]. Consequently, the variability in the assembly detail—high resolution picture of which is still unknown—if any, can be unraveled.

be removed for a new structure to get formed for the protein to move towards the native state. Thus the number of folding paths for a given protein would be dictated by the number and nature of structure preferences across the length of the chain.

In view of all this, it is important to understand the characteristics of the various denatured states, with regard to their topologies, heterogeneities and motional characteristics, their modulation due to changes in environmental conditions, etc. at atomic level detail. In vitro, different denatured states can be created by use of different denaturants, such as Gdn-HCl, urea, SDS, extreme pH conditions, etc. Although these may not exactly represent the denatured states, in vivo, they help sample the ensemble quite widely and thus allow investigation of the folding processes, in general.

In the background, we present here a comparative study of the structural and dynamics characteristics of urea-denatured and Gdn-HCl-denatured states of the GFP effector domain (CEDP) of dynamin, a crucial protein in clathrin mediated endocytosis. CEDP plays important roles both in dynamic assembly around the neck of the clathrin coated vesicles, and assists the N-terminal GDPase domain in GTP hydrolysis required for dynamin function [4,5]. The recombinant form of CEDP has been shown to self-assemble and form large aggregation-stead oligomers in vitro [6,7] even at micro-molar concentrations. We first describe the robust characterization parameters.

bio-ANS [4-(4'-nitro-1-aminophthalane 8-sulfonate) Molecular Probes, OR, USA] was prepared and the concentration was determined using the extinction coefficient,  $\epsilon_{280} = 23,000 \text{ cm}^2 \text{ M}^{-1}$ . Steady-state fluorescence emission spectra were recorded with  $\lambda_{exc} = 395 \text{ nm}$  on a Spex Fluorolog-DM2000 spectrofluorimeter at 27°C using a 1 cm path length cuvette with a band pass of 1.5 nm for both excitation and emission. The emission spectra were measured from 450 to 550 nm at a scan rate of  $1 \text{ nm s}^{-1}$ . The denaturation profiles of 10  $\mu\text{M}$  protein in Tris buffer (20 mM, pH 7.4), pre-equilibrated with varying concentration of the denaturant and bio-ANS (4  $\mu\text{M}$ ) for 12 h, were measured by monitoring the emission at 490 nm. The data were smoothed by three-point averaging to minimize errors due to denaturant concentration adjustments and were normalized using the following equation [10]:

$$F_{app} = \frac{S_0 - S_{inf}}{S_0 - S_0}$$

**References**

[1] J. Park, S. Sharma, *Biochem Biophys Res Commun* 331 (2005) 203–202.

[2] J.K. Kanai, M. Nishimura, *J. Biol. Chem.* 277 (2002) 40717–40724.

[3] J.K. Kanai, D.V. Belter, *Biochemistry* 41 (2002) 9634–9642.

[4] H. Fujita, A.J. Cox, *J. Biol. Chem.* 271 (1996) 221–228.

[5] R. Sankar, A.K. Ghosh, K. Kishore, C. Laxmi, *J. Biol. Chem.* 273 (2000) 2199–2204.

[6] S. Karmali, M. Combs, *J. Neurochem.* 81 (2003) 1819–1827.

[7] M.C. Akbar, A. Ahmad, V. Bulusu, *Biochemistry* 41 (2002) 3019–3027.

[8] J. Chugh, S. Sharma, D. Kumar, R.V. Hosur, *Biomed NMR Assignments* (2006), doi:10.1002/abm.20191.

[9] H.J. Down, P.E. Wright, *Nat. Struct. Mol. Biol.* 5 (1998) 699–903.

[10] H.J. Down, P.E. Wright, *Molbiol. Biophys.* 139 (1995) 236–238.

[11] H.J. Down, P.E. Wright, *Adv. Protein Chem.* 62 (2002) 311–360.

[12] H.J. Down, P.E. Wright, *Chem. Rev.* 100 (2000) 847–862.

[13] S. Schwarzinger, C.J. Knowl, T.R. Fox, P.E. Wright, *HJ. Down*, *NMR* 14 (2000) 68.

[14] S. Schwarzinger, C.J. Knowl, T.R. Fox, J. Cheng, P.E. Wright, H.J. Down, *J. Am. Chem. Soc.* 123 (2001) 2076–2079.

[15] J. Peeters, C. Fiedler, D. Miel, J. Hahn, D.J. McKay, D.J. Musakowski, K.A. Smith, *Chem. Commun.* 13 (2003) 1502–1503.

[16] S. Karmali, M. Combs, M. Okawa, S.B. Grisham, J. Wirtz, E. Duka, *J. Biol. Chem.* 274 (1999) 1191–1197.

[17] L.S. Liu, S.R. Whitaker, S.E. Bellsted, C.R. Muen, *J. Mol. Biol.* 344 (2000) 81–90.

[18] R.R. Conway, J.E. Kula, K.W. Platts, *Chem. Rev. Biochem. Mol. Biol.* 40 (2000) 1281–1293.

[19] S. Schwarzinger, P.E. Wright, H.J. Down, *Biochemistry* 41 (2002) 12681–12683.

[20] T.J. Jones, H. Liu, N.B. Dumas, S. Iyer, J. Chen, H. Zhang, D.C. Doney, S. Karmali, D. Gupta, L. Moshayesh, S.B. Prasad, E.J. Cohen, *Proc. Natl. Acad. Sci. USA* 94 (1997) 9009–9019.

[21] E. Iversen, J.C. Macdonald, C.N. Anolik, R. James, J. Krawinkel, N.J. Gaydon, *C.R. Moore, Biochemistry* 40 (2001) 11496–11507.

[42] J. Kope, *Exp. Devol. Biol. Mol. Biol.* 131 (2002) 160–132.

Scopus

Scopus/WoS 关注于摘要与引文部分。新一代信息导航工具。

Scopus

# EMTREE生命科学辞典

生命科学辞典，对生物医学文献进行主题分析、标引和检索时使用的权威性词表。

## 便于检索

- 超过73,000 个主题词汇以及超过 290,000个同义词汇

## 海量的药物以及医疗设备检索

- 化学名，商品名，实验室/研发代码，以及超过31,000个药物和化合物首选词汇 (FDA, EMA and WHO)
- 超过3,000个设备和医疗设备专属词汇 (e.g. endoscopes, catheters, prostheses) 以及数千个医疗过程相关词汇 (e.g. endoscopy, catheterization)

## 实时更新

- 每年3次更新最新的药物，疾病，生物体以及医疗过程的索引；包括所有的FDA以及EMA记录的药物名称和WHO从2000起记录的所有国际非专利名称(INNS).

## 包含词汇

- 包括所有的MeSH词汇，并且与超过23,000个CAS号进行了链接

# 以某一个药物为例：分析它的同义词

 **atorvastatin**  [29,651 Records](#)

**History**

This term was added to Emtree in 1990

**Synonyms**

所有同义词合集，包含MeSH词汇

2 (4 fluorophenyl) beta, delta dihydroxy 5 isopropyl 3 phenyl 4 phenylcarbamoyl 1h pyrrole 1 heptanoic acid; atorlip; atorvastatin calcium; atorvastatin calcium trihydrate; atovaryl; cardyl; ci 981; ci981; glustar; lipibec; lipitor; lipimar; liptonorm; lowlipen; sortis; storvas; tahor; torvast; totalip; xarator; ym 548; ym548; zarator

**CAS Registry Numbers**

[134523-00-5](#); [134523-03-8](#)

**Dorland's dictionary**

atorvastatin calcium = a synthetic HMG-CoA reductase inhibitor that acts as an antihyperlipidemic by inhibiting cholesterol synthesis; used in treatment of hypercholesterolemia and other forms of dyslipidemia, administered orally.

Lipitor = trademark for a preparation of atorvastatin calcium.

Definition from *Dorland's Medical Dictionary*, 32nd edition, copyright © 2011 by Elsevier. For more information please go to [www.dorlands.com](http://www.dorlands.com)

3.4.1 MeSH Synonyms

- |                                    |                                      |
|------------------------------------|--------------------------------------|
| 1. Anhydrous, Atorvastatin Calcium | 11. Calcium Trihydrate, Atorvastatin |
| 2. atorvastatin                    | 12. Calcium, Atorvastatin            |
| 3. atorvastatin calcium            | 13. CI 981                           |
| 4. atorvastatin calcium anhydrous  | 14. CI-981                           |
| 5. atorvastatin calcium hydrate    | 15. CI981                            |
| 6. atorvastatin calcium trihydrate | 16. Hydrate, Atorvastatin Calcium    |
| 7. atorvastatin, calcium salt      | 17. Lipitor                          |
| 8. Calcium Anhydrous, Atorvastatin | 18. liptonorm                        |
| 9. Calcium Hydrate, Atorvastatin   | 19. Trihydrate, Atorvastatin Calcium |
| 10. Calcium Salt Atorvastatin      |                                      |

实验室/研发代码


## EMTREE扩展搜索

Emtree + free text  
+ Synonyms  
'Key word' /Syn

### Synonyms

angiocardopathy; angiocardiovascular disease; cardiovascular complication; cardiovascular diseases; cardiovascular disorder; cardiovascular disturbance; cardiovascular lesion; cardiovascular syndrome; cardiovascular vegetative disorder; complication, cardiovascular; disease, cardiovascular; major adverse cardiovascular event


## EMTREE多级树状结构



狭义词汇

同义词

# 更广泛的文献收率范围和更深入的文献索引不会让你遗漏重要的检索结果：从药物进行对比





## 更广泛的文献收率范围和更深入的文献索引不会让你遗漏重要的检索结果：从制造商进行对比

Manufacturer	Embase	Not in MEDLINE
Abbott	6,503	1,283
Beckmann	9	2
Boston Scientific	10,212	1,854
Clearstream	7	1
Heartsine	7	1
Oceana Therapeutics	7	3
Merit	155	37
Sandoz	35	11
Siemens	24,046	3,583

# Embase 检索界面

Embase®

Search

Browse

Results

My tools

xian zhang

Logout



(1)



## Search

Broad search

AND  e.g. watson j

AND  e.g. american heart

[+ Add search field](#) [Show 0 results >](#)

### Search Tips

#### How do I use this search form?

Type into a text box. The autocomplete function will suggest complete words and phrases from Emtree.

To view results click 'Show # results'. The number of results is calculated as you build your search.

To search for a phrase, use single or double quotes around the phrase, e.g. 'heart attack'

#### What is Broad search?

It combines Emtree term explosion with free text search in all fields, e.g.


## Search

- 1) PICO
- 2) Quick
- 3) Advanced
- 4) Drug
- 5) Disease
- 6) Device
- 7) Article

## Browse

- 1) Emtree
- 2) Journals
- 3) Authors

## Result



## My Tools

- 1) Clipboard
- 2) Saved Clipboards
- 3) Email Alerts
- 4) Saved Searches

# Drug (药物检索)

## Drug Search

药物名称 (商品名或通用名)

药物副主题词

给药途径

e.g. 'low molecular weight heparin'

Search > Mapping ^ Date v Sources v Drug fields v Drug subheadings v Routes v Quick limits v EBM v Pub. types v Languages v Search tips v

Embase mapping options

Map to preferred term in Emtree  Limit to terms indexed in article as 'major focus'

Search > Mapping v Date v Sources v Drug fields v Drug subheadings ^ Routes v Quick limits v EBM v Pub. types v Languages v Search tips v

Subheadings

- Adverse drug reaction
- Clinical trial
- Drug administration
- Drug analysis
- Drug combination
- Drug comparison

OR AND

Routes of drug administration

<input type="checkbox"/> Buccal drug administration	<input type="checkbox"/> Intrabursal drug administration	<input type="checkbox"/> Intracisternal drug administration
<input type="checkbox"/> Epidural drug administration	<input type="checkbox"/> Intracameral drug administration	<input type="checkbox"/> Intradermal drug administration
<input type="checkbox"/> Inhalational drug administration	<input type="checkbox"/> Intracardiac drug administration	<input type="checkbox"/> Intrahepatic drug administration
<input type="checkbox"/> Intraarterial drug administration	<input type="checkbox"/> Intracavernous drug administration	<input type="checkbox"/> Intralesional drug administration
<input type="checkbox"/> Intraarticular drug administration	<input type="checkbox"/> Intracerebral drug administration	<input type="checkbox"/> Intralymphatic drug administration
<input type="checkbox"/> Intrabronchial drug administration	<input type="checkbox"/> Intracerebroventricular drug administration	<input type="checkbox"/> Intrauterine drug administration
<input type="checkbox"/> Intramuscular drug administration	<input type="checkbox"/> Intraspinal drug administration	<input type="checkbox"/> Intravaginal drug administration
<input type="checkbox"/> Intranasal drug administration	<input type="checkbox"/> Intrathecal drug administration	<input type="checkbox"/> Intravenous drug administration
<input type="checkbox"/> Intraocular drug administration	<input type="checkbox"/> Intratracheal drug administration	<input type="checkbox"/> Intravesical drug administration
<input type="checkbox"/> Intraosseous drug administration	<input type="checkbox"/> Intratumoral drug administration	<input type="checkbox"/> Intravitreal drug administration
<input type="checkbox"/> Intraperitoneal drug administration	<input type="checkbox"/> Intratympanic drug administration	<input type="checkbox"/> Oral drug administration
<input type="checkbox"/> Intrapleural drug administration	<input type="checkbox"/> Intraurethral drug administration	
<input type="checkbox"/> Parenteral drug administration	<input type="checkbox"/> Subcutaneous drug administration	
<input type="checkbox"/> Periocular drug administration	<input type="checkbox"/> Sublabial drug administration	
<input type="checkbox"/> Rectal drug administration	<input type="checkbox"/> Sublingual drug administration	
<input type="checkbox"/> Regional Perfusion	<input type="checkbox"/> Topical drug administration	
<input type="checkbox"/> Retrobulbar drug administration	<input type="checkbox"/> Transdermal drug administration	
<input type="checkbox"/> Subconjunctival drug administration		

OR AND

提供多达16种药物专题检索：包括药物不良反应，药物临床试验，药理学，药代动力学等

提供用药方式的检索：包括口服、肌肉注射、静脉注射等48个方式

# Embase 关于某个药物的临床试验文献的查询

检索需求：查询关于吉非替尼的临床试验研究的文献

输入药物名称

Embase®

Search ▾ Browse ▾ Results My tools ▾ xian zhang 田 Logout ⚙️ 🔔(1)

Drug Search

[Search >](#) [Mapping ^](#) [Date ▾](#) [Sources ▾](#) [Drug fields ▾](#) [Drug subheadings ▾](#) [Routes ▾](#) [Quick limits ▾](#) [EBM ▾](#) [Pub. types ▾](#) [Languages ▾](#) [Search tips ▾](#)

Embase mapping options Clear page selections Collapse

Map to preferred term in Emtree  Limit to terms indexed in article as 'major focus'

Search also as free text in all fields

Explode using narrower Emtree terms

Search as broadly as possible

Subheadings Clear page selections Collapse

- |  |   |  |
|--|---|--|
| <input type="checkbox"/> Adverse drug reaction     | <input type="checkbox"/> Drug concentration | <input type="checkbox"/> Endogenous compound |
| <input checked="" type="checkbox"/> Clinical trial | <input type="checkbox"/> Drug development   | <input type="checkbox"/> Pharmaceutics       |
| <input type="checkbox"/> Drug administration       | <input type="checkbox"/> Drug dose          | <input type="checkbox"/> Pharmacoeconomics   |
| <input type="checkbox"/> Drug analysis             | <input type="checkbox"/> Drug interaction   | <input type="checkbox"/> Pharmacokinetics    |
| <input type="checkbox"/> Drug combination          | <input type="checkbox"/> Drug therapy       | <input type="checkbox"/> Pharmacology        |
| <input type="checkbox"/> Drug comparison           | <input type="checkbox"/> Drug toxicity      |  |
- OR  AND

选择临床试验对应的选项

# 一共查询到gefitinib关于临床试验的文章有4492篇

Embase®

Search ▾ Browse ▾ Results My tools ▾ xian zhang 田 Logout ⚙

- Sources ▾
- Drugs ▾
- Diseases ▾
- Devices ▾
- Floating Subheadings ▾
- Age ▾
- Gender ▾
- Study types ▾
- Publication types ▾
- Journal titles ▾
- Publication years ▾
- Authors ▾
- Conference Abstracts ▾
- Drug Trade Names ▾
- Drug Manufacturers ▾
- Device Trade Names ▾
- Device Manufacturers ▾

4,496 results for search #1 [Set email alert](#) [Set RSS feed](#) [Search details](#)

**Results** View | Print | Export | Email | Order | Add to Clipboard 1 — 25 [➤](#)

Select number of items ▾ Selected: 0 (clear) Show all abstracts | Sort by:  Relevance  Publication Year  Entry Date

1 **New Targets in Non-Small Cell Lung Cancer**  
 Park S.J., More S., Murtuza A., Woodward B.D., Husain H.  
*Hematology/Oncology Clinics of North America* 2017 31:1 (113-129)  
 Embase [Abstract](#) [Index Terms](#) [View Full Text](#)

With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non-small cell lung cancer. The clinical success of tyrosine kinase inhibitors against epidermal growth factor receptor and anaplastic lymphoma kinase activation has shifted treatment emphasis the separation of subsets of lung cancer and genotype-directed therapy. Advances have validated oncogenic driver genes and led to the development of targeted agents. This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations.  
 © 2016 Elsevier Inc.

2 **Treatment of Locally Advanced Non-Small Cell Lung Cancer**  
 Tam K., Daly M., Kelly K.  
*Hematology/Oncology Clinics of North America* 2017 31:1 (45-57)  
 Embase [Abstract](#) [Index Terms](#) [View Full Text](#)

3 **Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results**  
 Kubo E., Yamamoto N., Nokihara H., Fujiwara Y., Horinouchi H., Kanda S., Goto Y., Ohe Y.  
*Molecular and Clinical Oncology* 2017 6:1 (56-62)  
 Embase [Abstract](#) [Index Terms](#) [View Full Text](#)

描述了一种治疗非小细胞肺癌的新靶点，随着基因组学的发展，靶向治疗已经可以预见在癌症治疗中的好处，本文着重对比了各种治疗的方法，包括相应的临床试验例如（ROS1重排,RET融合 BRAF突变等

**Drug Terms**

altiratinib, antineoplastic agent, B Raf kinase, cabozantinib, capmatinib, ceritinib, crizotinib, ds 6051b, emibetuzumab, entrectinib, erlotinib, foretinib, **gefitinib**, glesatinib, K ras protein, lorlatinib, ly 3009120, n [5 [2 (2,5 difluorophenyl) 1 pyrrolidinyl]pyrazolo[1,5 a]pyrimidin 3 yl] 3 hydroxy 1 pyrrolidinecarboxamide, NTRK1 protein, plx 7486, plx 8394, protein Ret, protein tyrosine kinase, ROS1 protein, sar 125844, scatter factor receptor, sitravatinib, tepotinib, tsr 011, unclassified drug, unindexed drug

**Disease Terms**

BRAF gene, c MET gene, lung adenocarcinoma, non small cell lung cancer, NTRK1 gene, RET gene, ROS1 gene


**Other Terms**

drug efficacy, gene amplification, gene expression, gene fusion, gene mutation, human, molecularly targeted therapy, oncogene, oncogene K ras, phase 1 clinical trial (topic), phase 2 clinical trial (topic), priority journal, review, somatic mutation

# 可以通过Results Filters对检索结果进行相应的筛选和查找

Source可以筛选文章的来源

Drugs 可以挑选出这些文章中还出现了其他药物的五种关键分类的文章



Drugs ^

<input type="checkbox"/> gefitinib	Details ▶	4496
<input type="checkbox"/> erlotinib	Details ▶	2928
<input type="checkbox"/> paclitaxel	Details ▶	1995
<input type="checkbox"/> cisplatin	Details ▶	1993
<input type="checkbox"/> cetuximab	Details ▶	1906
<input type="checkbox"/> epidermal growth factor receptor	Details ▶	1877
<input type="checkbox"/> bevacizumab	Details ▶	1848
<input type="checkbox"/> carboplatin	Details ▶	1831

> Export

Key subheadings X

<input type="checkbox"/> adverse drug reaction	822
<input type="checkbox"/> drug combination	1292
<input type="checkbox"/> drug comparison	618
<input type="checkbox"/> drug interaction	113
<input type="checkbox"/> drug therapy	2719

可以分别挑选出来自Embase ,Medline 以及两者同时收录的文章

五种关键的分类 (Key subheading) 包括药物不良反应, 药物联用, 药物比较, 药物相互作用, 药物之类五大分类

## 可以通过Results Filters对检索结果进行相应的筛选和查找

Disease 可以挑选出这些文章中还出现了其他疾病的两种关键分类的文章

**Diseases**

Disease	Details	Count
<input type="checkbox"/> non small cell lung cancer	Details ▶	1646
<input type="checkbox"/> diarrhea	Details ▶	1049
<input type="checkbox"/> advanced cancer	Details ▶	727
<input type="checkbox"/> fatigue	Details ▶	667
<input type="checkbox"/> neutropenia	Details ▶	633
<input type="checkbox"/> nausea	Details ▶	598
<input type="checkbox"/> rash	Details ▶	557
<input type="checkbox"/> breast cancer	Details ▶	549

**Key subheadings**

<input type="checkbox"/> drug therapy	1619
<input type="checkbox"/> side effect	5

> Export

两种关键的分类 (Key Subheading)包括药物治疗和副作用

Age 可以帮助你挑选出参加临床试验的不同年纪的人群的文章

**Age**


<input type="checkbox"/> Child (1-12)	20
<input type="checkbox"/> Preschool child (1-6)	4
<input checked="" type="checkbox"/> School child (7-12)	2
<input type="checkbox"/> Adolescent	12
<input type="checkbox"/> Young adult	2
<input type="checkbox"/> Adult	381
<input type="checkbox"/> Middle aged	15
<input type="checkbox"/> Aged	370

> Export


这些关于参与人群的年龄分类包括：胚胎，胎儿，新生儿，婴幼儿，1-12岁的小孩，学龄前儿童（1-6岁），学校儿童（7-12岁），青少年，青年人，成年人，中年人，老年人，高龄老年人

## 可以通过Results Filters对检索结果进行相应的筛选和查找

Gender可以帮你挑选出你想看的性别的相应的文章



Study type 可以帮你挑选出属于不同研究类型的文章



研究的类型包括：关于人类的，临床试验的，非人类的，临床三期，临床二期，对照研究，随机对照临床试验，Meta analysis，systematic review，体外研究，循证医学，剂量比较



# 可以通过Results Filters对检索结果进行相应的筛选和查找

Journal Titles 帮助你筛选你来自于不同期刊的文章

Journal titles	
<input type="checkbox"/> Annals of Oncology	143
<input type="checkbox"/> Expert Review of Anticancer Therapy	142
<input type="checkbox"/> Clinical Lung Cancer	134
<input type="checkbox"/> Clinical Cancer Research	107
<input type="checkbox"/> Journal of Clinical Oncology	104
<input type="checkbox"/> Lung Cancer	92
<input type="checkbox"/> Oncologist	92

> Export

Publication years and Authors 帮助你选择来自于不同作者和年份的相应文章

Publication years	
<input type="checkbox"/> 2017	3
<input type="checkbox"/> 2016	131
<input type="checkbox"/> 2015	157
<input type="checkbox"/> 2014	181
<input type="checkbox"/> 2013	297
<input type="checkbox"/> 2012	325
<input type="checkbox"/> 2011	300
<input type="checkbox"/> 2010	353
<input type="checkbox"/> 2009	340

Authors	
<input type="checkbox"/> Gridelli C.	64
<input type="checkbox"/> Ciardiello F.	46
<input type="checkbox"/> Giaccone G.	46
<input type="checkbox"/> Herbst R.S.	43
<input type="checkbox"/> Rossi A.	41
<input type="checkbox"/> Belani C.P.	40
<input type="checkbox"/> Cappuzzo F.	38
<input type="checkbox"/> Malone P.	38
<input type="checkbox"/> Sprinckli M.A.	37

> Export

例如里面出现的:

1. [The Lancet Oncology](#) 柳叶刀肿瘤学
2. [Nature Reviews Clinical Oncology](#)
3. [British Journal of Cancer](#)

可以紧盯领域内的牛人的最新的文章

# 可以通过Results Filters对检索结果进行相应的筛选和查找

Drug Trade Names 帮助你筛选涉及到药品商品名的文章

Drug Trade Names	
<input type="checkbox"/> Iressa	1566
<input type="checkbox"/> tarceva	964
<input type="checkbox"/> zd 1839	827
<input type="checkbox"/> erbitux	584
<input type="checkbox"/> osi 774	509
<input type="checkbox"/> avastin	502
<input type="checkbox"/> herceptin	436
<input type="checkbox"/> zd 6474	362
<input type="checkbox"/> cleaver	351

> Export

例如非小细胞肺癌中的常用药物：易瑞沙，特罗凯等，同时还包含一些在研究的化合物的实验室代码例如 (zd 1839, ccl 799, ptk 787,azd 2171等

Drug Manufactures 帮助你筛选涉及到药品制造商发的文章

Drug Manufacturers	
<input type="checkbox"/> Astra Zeneca	880
<input type="checkbox"/> Genentech	545
<input type="checkbox"/> Pfizer	443
<input type="checkbox"/> Novartis	437
<input type="checkbox"/> Imclone	303
<input type="checkbox"/> Glaxo SmithKline	288
<input type="checkbox"/> Osi	270
<input type="checkbox"/> Hoffmann La Roche	265
<input type="checkbox"/> Bristol Myers Squibb	243

> Export

这些制药企业包括：阿斯利康，基因泰克，辉瑞，诺华，GSK等

# Embase 关于拓展某个药物的适应症(indications)的查询

检索需求：查询关于紫杉醇的适应症拓展的文献

紫杉醇是从短叶紫杉树皮中提取的具有抗肿瘤作用的活性物质，通过II-III临床研究，紫杉醇主要适用于卵巢癌和乳腺癌，那如何查询紫杉醇关于其他适应症研究的文章

Embase®

Search ▾ Browse ▾ Results My tools ▾ xian zhang ④ Logout ⚙️ 🔔(1) ⓘ

## Drug Search

Paclitaxel

Search > Mapping ▾ Date ▾ Sources ▾ Drug fields ▾ Drug subheadings ^ Routes ▾ Quick limits ▾ EBM ▾ Pub. types ▾ Languages ▾ Search tips ▾

Subheadings Clear page selections Collapse

<input type="checkbox"/> Adverse drug reaction	<input type="checkbox"/> Drug concentration	<input type="checkbox"/> Endogenous compound
<input type="checkbox"/> Clinical trial	<input type="checkbox"/> Drug development	<input type="checkbox"/> Pharmaceutics
<input type="checkbox"/> Drug administration	<input type="checkbox"/> Drug dose	<input type="checkbox"/> Pharmacoeconomics
<input type="checkbox"/> Drug analysis	<input type="checkbox"/> Drug interaction	<input type="checkbox"/> Pharmacokinetics
<input type="checkbox"/> Drug combination	<input checked="" type="checkbox"/> Drug therapy	<input type="checkbox"/> Pharmacology
<input type="checkbox"/> Drug comparison	<input type="checkbox"/> Drug toxicity	

OR  AND

药物名称：紫杉醇 Paclitaxel

选择Drug Therapy(药物治疗)这个分类

# 一共查询到关于紫杉醇药物治疗的相关文献43590篇

Embase®

Search ▾ Browse ▾ Results My tools ▾ xian zhang 田 Logout ⚙️ 🔔(1) ⓘ

## Results Filters

+ Expand - Collapse all Apply &gt;

## Sources ▾

## Drugs ▾

- paclitaxel Details ▶ 43590
- carboplatin Details ▶ 19460
- cisplatin Details ▶ 18423
- docetaxel Details ▶ 13380
- doxorubicin Details ▶ 13247
- gemcitabine Details ▶ 11134
- cyclophosphamide Details ▶ 11027
- fluorouracil Details ▶ 10732
- anthracycline agent Details ▶ 8671

&gt; Export

## Diseases ▾

## Devices ▾

## Floating Subheadings ▾

 History Save | Delete | Print view | Export | Email Combine > using  And  Or

^ Collapse

 #1 'paclitaxel/exp/dd\_dt'

43,590

43,590 results for search #1 [Set email alert](#) [Set RSS feed](#) [Search details](#) Results View | Print | Export | Email | Order | Add to Clipboard

1 — 25 &gt;

Select number of items Selected: 0 (clear) [Show all abstracts](#) | Sort by:  Relevance  Publication Year  Entry Date

- 1 Human papillomavirus (HPV): A criterion for therapeutic decision in squamous cell carcinoma of the head and neck?  
Vermorken J.B.  
*Recent Results in Cancer Research* 2017 206 (137-147)  
Embase [Abstract](#) [Index Terms](#) [View Full Text](#)
- 2 Systemic treatment in HPV-induced recurrent or metastatic HNSCC  
Rieke D.T., Keilholz U.  
*Recent Results in Cancer Research* 2017 206 (149-160)  
Embase [Abstract](#) [Index Terms](#) [View Full Text](#)
- 3 Optimizing radiotherapy in HPV-associated oropharyngeal cancer patients  
Langendijk J.A., Steenbakkers R.J.H.M.  
*Recent Results in Cancer Research* 2017 206 (161-171)  
Embase [Abstract](#) [Index Terms](#) [View Full Text](#)

通过Key Subheading 去筛选关于药物治疗的文章，看看涉及到了哪些适应症

The screenshot displays a research database interface. On the left, a list of drugs is shown with checkboxes and their respective article counts:

Drug	Count
paclitaxel	43590
carboplatin	19460
cisplatin	18423
docetaxel	13380
doxorubicin	13247
gemcitabine	11134
cyclophosphamide	11027
fluorouracil	10732
antineoplastic agent	8011

In the center, a 'Key subheadings' window is open, listing various categories with their counts:

Subheading	Count
adverse drug reaction	11016
drug combination	25418
drug comparison	5160
drug interaction	1456
drug therapy	43590

On the right, a 'Drug therapy' window is open, showing a search bar and a list of cancer types with their counts:

Cancer Type	Count
breast cancer	4428
lung non small cell cancer	2649
ovary cancer	2259
advanced cancer	2156
ovary carcinoma	991
non small cell lung cancer	806
stomach cancer	719
lung cancer	564
breast metastasis	530
metastasis	526
uterine cervix cancer	500
pancreas cancer	480
melanoma	452
lung adenocarcinoma	442
breast carcinoma	399
triple negative breast cancer	378
coronary artery disease	376
squamous cell carcinoma	351
endometrium cancer	344
solid tumor	315

An orange arrow points from the 'Drug therapy' window towards the text below.

不仅仅包括紫杉醇最主要的适应症例如：乳腺癌，非小细胞肺癌，卵巢肿瘤，还包括了一些其他的适应症研究例如（胃癌，胰腺癌，黑色素瘤，子宫内膜癌，头颈癌等多达500种以上相关疾病的治疗研究的文章，有效的查询和寻找一些想要研究和拓展的领域的文章

### 3) Embase 如何查询药物 (Statins) 不良反应

检索需求：查询Statins他汀类药物的不良反应

Browse Emtree

**Query Builder** ▼  
Build a multi-term search query

Find Term Browse by Facet

Type word or phrase (without quotes)

statins X

Find Term >

statins  
use preferred term: [hydroxymethylglutaryl coenzyme A reductase inhibitor](#)

在Emtree主题字表中输入“Statins”

Browse Emtree

**Query Builder** ▼  
Build a multi-term search query

Find Term Browse by Facet

Type word or phrase (without quotes)

[hydroxymethylglutaryl coenzyme A reductase inhibitor](#) X

Find Term >

For term: 'hydroxymethylglutaryl coenzyme A reductase inhibitor'  
Extend your search:  Explode  As major focus

Take this query to Drug Search > Add to Query Builder >

点击“Take this query to Drug Search”，包含所有他汀类的下位词

# Embase 如何查询药物 (Statins) 不良反应

检索需求：查询Statins他汀类药物的不良反应

在Emtree中输入“Stains” 自动  
匹配到Emtree中的关键词

Browse Emtree

**Query Builder** ▼  
Build a multi-term search query

Find Term Browse by Facet

Type word or phrase (without quotes)  
statins

statins  
use preferred term: [hydroxymethylglutaryl coenzyme A reductase inhibitor](#)

Drug Search

'hydroxymethylglutaryl coenzyme A reductase inhibitor'/exp

Search > Mapping Date Sources Drug fields Drug subheadings Routes Quick limits EBM Pub. types Languages Search tips

Subheadings Clear page selections Collapse

<input checked="" type="checkbox"/> Adverse drug reaction	<input type="checkbox"/> Drug concentration	<input type="checkbox"/> Endogenous compound
<input type="checkbox"/> Clinical trial	<input type="checkbox"/> Drug development	<input type="checkbox"/> Pharmaceuticals
<input type="checkbox"/> Drug administration	<input type="checkbox"/> Drug dose	<input type="checkbox"/> Pharmacoeconomics
<input type="checkbox"/> Drug analysis	<input type="checkbox"/> Drug interaction	<input type="checkbox"/> Pharmacokinetics
<input type="checkbox"/> Drug combination	<input type="checkbox"/> Drug therapy	<input type="checkbox"/> Pharmacology
<input type="checkbox"/> Drug comparison	<input type="checkbox"/> Drug toxicity	

OR  AND

限定副主题词  
“Adverse drug reaction”

### 3) Embase 如何查询药物 (Statins) 不良反应

检索需求：查询Statins他汀类药物的不良反应

The screenshot shows the Embase search interface. The search query is 'hydroxymethylglutaryl coenzyme a reductase inhibitor/exp/dd\_ae'. The search results are displayed in a table with columns for item number, search criteria, and the number of results. Item #6 is highlighted with a red box, showing 11,380 results. The search filters on the left include Sources, Drugs, Diseases, Devices, Floating Subheadings, and Age. The search results table includes a 'History' section with a 'Combine' button and a 'Results' section with a 'View' button. The search results table also includes a 'Set email alert' button, a 'Set RSS feed' button, and a 'Search details' button. The search results table also includes a '1 - 25' pagination control.

Item	Search Criteria	Results
#6	'hydroxymethylglutaryl coenzyme a reductase inhibitor'/exp/dd_ae	11,380
#5	#3 AND 'adverse drug reaction'/lnk AND 2016:py	749
#4	#3 AND 'adverse drug reaction'/lnk	25,131
#3	'hydroxymethylglutaryl coenzyme a reductase inhibitor'/exp	114,631
#2	'hydroxymethylglutaryl coenzyme a reductase inhibitor'/exp/dd_ae	11,380
#1	'hydroxymethylglutaryl coenzyme a reductase inhibitor'/exp/dd_ae	11,380

The screenshot shows the 'Diseases' filter section of the Embase search results. The 'side effect' filter is selected, and the results are displayed in a table with columns for the disease name, 'Details', and the number of results. The results are sorted by the number of results in descending order. The search results table includes a 'Details' button for each row and an 'Export' button at the bottom.

Disease	Details	Results
side effect	Details ▶	3656
rhabdomyolysis	Details ▶	3324
hypercholesterolemia	Details ▶	3170
myopathy	Details ▶	2767
myalgia	Details ▶	2600
cardiovascular disease	Details ▶	2565
dyslipidemia	Details ▶	2105
hyperlipidemia	Details ▶	1817
diabetes mellitus	Details ▶	1748

查询到11,380篇文献涉及到不良反应

设计到的副反应的描述：心血管疾病、肝损害、过敏反应、眼外肌麻痹、性功能障碍、多尿、消化系统反应、关节痛、下肢不宁综合征



## 来自美国FDA的推荐

FDA 对药物上市后的安全性监测有严格的法规要求

### VI.B.1.1.2. Literature reports

The scientific and medical literature is a significant source of information for the monitoring of the safety profile and of the risk-benefit balance of medicinal products, particularly in relation to the detection of new safety signals or emerging safety issues. Marketing authorization holders are therefore expected to maintain awareness of possible publications through a systematic literature review of widely used reference databases (e.g. Medline, Excerpta Medica or Embase) no less frequently than once a week. The marketing authorization holder should ensure that the literature review includes the use of reference databases that contain the largest reference of articles in relation to the medicinal product properties.

### A. Good Reporting Practice

Spontaneous case reports of adverse events submitted to the sponsor and FDA, and reports from other sources, such as the medical literature or clinical studies, may generate signals of adverse effects of drugs. The quality of the reports is critical for appropriate evaluation of the relationship between the product and adverse events. FDA recommends that sponsors make a reasonable attempt to obtain complete information for case assessment during initial contacts and subsequent follow-up, especially for serious events,<sup>4</sup> and encourages sponsors to use trained

EMBASE和MEDLINE是被推荐用于查询不良反应的数据库



ELSEVIER



Thanks For Your Attention!



Any questions? Contact:

**张弦**

**185-1612-9056**

**[e.zhang@elsevier.com](mailto:e.zhang@elsevier.com)**